Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Shares Outstanding (2020 - 2025)

Immunocore Holdings (IMCR) has disclosed Shares Outstanding for 6 consecutive years, with $50.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.25% to $50.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.7 million through Dec 2025, up 1.25% year-over-year, with the annual reading at $50.7 million for FY2025, 1.25% up from the prior year.
  • Shares Outstanding hit $50.7 million in Q4 2025 for Immunocore Holdings, roughly flat from $50.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $59.1 million in Q4 2021 to a low of $5.8 million in Q4 2023.
  • Historically, Shares Outstanding has averaged $35.2 million across 5 years, with a median of $49.5 million in 2023.
  • Biggest five-year swings in Shares Outstanding: soared 40.89% in 2021 and later tumbled 88.02% in 2024.
  • Year by year, Shares Outstanding stood at $59.1 million in 2021, then fell by 4.61% to $56.4 million in 2022, then fell by 11.84% to $49.7 million in 2023, then increased by 0.68% to $50.1 million in 2024, then increased by 1.25% to $50.7 million in 2025.
  • Business Quant data shows Shares Outstanding for IMCR at $50.7 million in Q4 2025, $50.5 million in Q3 2025, and $50.4 million in Q2 2025.